Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
153.58
+5.02 (+3.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Why Gorilla Technology Group Shares Are Trading Lower By 25%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 20, 2023
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916.
Via
Benzinga
Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories
September 19, 2023
Bloomberg
Via
Benzinga
The Latest Analyst Ratings for BeiGene
September 12, 2023
Via
Benzinga
Analyst Expectations for BeiGene's Future
August 17, 2023
Via
Benzinga
Why Are BeiGene Shares Trading Lower Today
July 11, 2023
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to
Via
Benzinga
What's Happening With Beigene Shares During Wednesday's Session
June 21, 2023
Beigene Ltd (NASDAQ: BGNE) shares are trading lower by 3.41% to $185.03 Wednesday morning on downward momentum following Tuesday weakness.
Via
Benzinga
Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact
September 19, 2023
BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS).
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
September 12, 2023
Via
Benzinga
Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session
September 11, 2023
U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Recap: BeiGene Q1 Earnings
May 04, 2023
Via
Benzinga
BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study
April 20, 2023
Via
Benzinga
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 11, 2023
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...
Via
Benzinga
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
August 29, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
August 29, 2023
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to...
Via
Benzinga
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
August 23, 2023
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2023
August 17, 2023
Via
Benzinga
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
August 12, 2023
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies...
Via
Talk Markets
Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says
July 25, 2023
William Blair has initiated coverage on AbbVie Inc (NYSE: ABBV) with a
Via
Benzinga
BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View
July 17, 2023
Citi initiated coverage on BeiGene Ltd (NASDAQ: BGNE) with a price target of $275 and a B
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
July 17, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
June 30, 2023
Via
Benzinga
Why This BeiGene Analyst Slashes Forecast By Almost 42%
June 30, 2023
BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks.
Via
Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
June 30, 2023
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...
Via
Benzinga
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
June 15, 2023
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics
Via
Benzinga
Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket
June 15, 2023
Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares gained 139.8% to $26.54 in pre-market trading.
Via
Benzinga
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 15, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
May 25, 2023
Via
Benzinga
Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis
May 22, 2023
Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...
Via
Benzinga
What's Going On With Immix Biopharma Stock Today
May 03, 2023
Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'
Via
Benzinga
3 Top Biotech Stocks Defying the Bear Market
April 25, 2023
All three companies have therapies with strong sales potential.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.